Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | FPR2 | P25090 | 9/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FPR3 | P25089 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727476 | 0.85 | FPR2 (0.77) | ALDH1A1SMN1; SMN2MEN1KMT2AFPR2 | |
| SCHEMBL20009932 | 0.85 | PKM (0.63) | ALDH1A1SMN1; SMN2MEN1KMT2AFPR2 | |
| SCHEMBL20013750 | 0.84 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2FPR2PKMLMNA | |
| SCHEMBL728702 | 0.84 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2FPR2PKMFPR3 | |
| SCHEMBL21310365 | 0.82 | HTT (0.62) | ALDH1A1SMN1; SMN2MEN1KMT2AFPR2 | |
| SCHEMBL726965 | 0.82 | FPR2 (0.58) | ALDH1A1SMN1; SMN2MEN1KMT2AFPR2 | |
| SCHEMBL20013749 | 0.78 | MEN1 (1.00) | ALDH1A1SMN1; SMN2MEN1KMT2APKM | |
| SCHEMBL728698 | 0.78 | FPR2 (0.74) | ALDH1A1SMN1; SMN2FPR2PKMFPR3 | |
| SCHEMBL726966 | 0.78 | FPR2 (0.78) | ALDH1A1SMN1; SMN2MEN1KMT2AFPR2 | |
| SCHEMBL726819 | 0.76 | FPR2 (1.00) | ALDH1A1SMN1; SMN2FPR2PKMFPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897609-B1 | METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURS | UEA ENTERPRISES LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023209077-A1 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | UEA ENTERPRISES LIMITED (GB) | 2023-11-02 | — | — | WO | disclosed |
| WO-2020128534-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURS | UEA ENTERPRISES LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| US-10329246-B2 | RUNX2 transcription factor inhibitors and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180086696-A1 | RUNX2 Transcription Factor Inhibitors and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086696-A1 | RUNX2 Transcription Factor Inhibitors and Uses Thereof | CBFB, RUNX1, NCOA3 | ALDH1A1 4181/4885SMN1; SMN2 3505/4885MEN1 1664/4885 |
| US-10329246-B2 | RUNX2 transcription factor inhibitors and uses thereof | CBFB, RUNX1, NCOA3 | ALDH1A1 4181/4885SMN1; SMN2 3505/4885MEN1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.